… bortezomib, cyclophosphamide and betamethasone gives quicker, better and more durable response than VAD/CyBet regimens: results from a Swedish retrospective …
K Uttervall, J Admasie, E Alici, J Lund, J Liwing… - Acta …, 2013 - karger.com
… Bortezomib, cyclophosphamide and betamethasone (VCB) were introduced in Sweden …
The purpose of the present retrospective study was to evaluate the impact of VAD or CyBet …
The purpose of the present retrospective study was to evaluate the impact of VAD or CyBet …
Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a …
M Kropff, M Vogel, G Bisping, R Schlag, R Weide… - Annals of …, 2017 - Springer
… in this retrospective analysis was much higher than that seen … , in combination with bortezomib
and/or betamethasone, or with … In conclusion, both treatment regimens appeared similar in …
and/or betamethasone, or with … In conclusion, both treatment regimens appeared similar in …
[PDF][PDF] Superiority of CyBorD Over VAD is More Evident in First than in Second Line Treatment of Multiple Myeloma
MM El Gammal, MA Samra, NH Ibrahim… - Ann Blood Cancer … - researchgate.net
… with Dexamethasone, or Betamethasone (CyBet), replaced VAD as the standard induction
… with results of the Swedish retrospective study in 2012, PFS was better with bortezomib [18]. …
… with results of the Swedish retrospective study in 2012, PFS was better with bortezomib [18]. …
[HTML][HTML] Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009-2013
K Remes, P Anttila, R Silvennoinen, M Putkonen… - PloS one, 2018 - journals.plos.org
… Retrospective data from the Swedish National Registry reveals … of other retrospective studies
from the Nordics [8, 21] and … They show that bortezomib is the mainstay of treatment from …
from the Nordics [8, 21] and … They show that bortezomib is the mainstay of treatment from …
Weekly Cyclophosphamide-Bortezomib-Dexamethasone Induction Performs Comparably to Twice-Weekly Dosing with Respect to Both Response Rates and Survival …
C Thirunavukarasu, N Weber, K Morris… - Acta …, 2020 - karger.com
… and once-weekly CBD regimens in patients who underwent … the limitations of our retrospective
study design, weekly CBD … injury to persons or property resulting from any ideas, methods, …
study design, weekly CBD … injury to persons or property resulting from any ideas, methods, …
[图书][B] Biological Markers and Treatment as Prognostic Factors in Multiple Myeloma
K Uttervall - 2015 - search.proquest.com
… received bortezomib, cyclophosphamide, betamethasone (VCB). We found that the VCB
patients had a quicker and better response than the VAD/CyBet group as … retrospective analysis …
patients had a quicker and better response than the VAD/CyBet group as … retrospective analysis …
Clinical Studies in Multiple Myeloma
J Lund - 2016 - search.proquest.com
… betamethasone gives quicker, better and more durable response than VAD/CyBet regimens:
results from a Swedish … Our own retrospective study could show that use of Thal, Bor or Len …
results from a Swedish … Our own retrospective study could show that use of Thal, Bor or Len …